ATC Group: N02CD03 Fremanezumab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N02CD03 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N02 Analgesics
3 N02C Antimigraine preparations
4 N02CD Calcitonin gene-related peptide (CGRP) antagonists
5 N02CD03

Active ingredients in N02CD03

Active Ingredient

Fremanezumab is a humanised IgG2Δa/kappa monoclonal antibody which selectively binds the calcitonin gene-related peptide (CGRP) ligand and blocks both CGRP isoforms (α- and β-CGRP) from binding to the CGRP receptor. It is believed that prevention of migraine is obtained by its effect modulating the trigeminal system.

Related product monographs

Document Type Information Source  
 AJOVY Solution for injection MPI, EU: SmPC European Medicines Agency (EU)

United States medicines

Medicines classified under this ATC code globally

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

New Zealand (NZ)

Poland (PL)

Romania (RO)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.